Liver injury during highly pathogenic human coronavirus infections

Liver International

Volumn 40, Issue 5, 2020, Pages 998-1004

  Xu, Ling ^a,b   Liu, Jia ^a,b   Lu, Mengji ^b,c   Yang, Dongliang ^a,b   Zheng, Xin ^a,b  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

COVID 19; liver injury; MERS; SARS; SARS CoV 2

Indexed keywords

CORONAVIRUS DISEASE 2019; CORONAVIRUS INFECTION; HUMAN; LIVER INJURY; MIDDLE EAST RESPIRATORY SYNDROME; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; NONHUMAN; REVIEW; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; BETACORONAVIRUS; DISEASE EXACERBATION; LIVER; PANDEMIC; PATHOLOGY; PATHOPHYSIOLOGY; VIROLOGY; VIRUS PNEUMONIA;

BETACORONAVIRUS; CORONAVIRUS INFECTIONS; DISEASE PROGRESSION; HUMANS; LIVER; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; PANDEMICS; PNEUMONIA, VIRAL; SARS VIRUS;

EID: 85082532828     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.14435     Document Type: Review

References (62)

1. Su S, Wong G, Shi W, et al. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol. 2016;24(6):490-502.
2. Peiris J, Lai ST, Poon L, et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet. 2003;361(9366):1319-1325.
3. Kupferschmidt K. Researchers scramble to understand camel connection to MERS. Science. 2013;341(6147):702.
4. Zhu NA, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-733.
5. Drosten C, Günther S, Preiser W, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med. 2003;348(20):1967-1976.
6. Chang H-L, Chen K-T, Lai S-K, et al. Hematological and biochemical factors predicting SARS fatality in Taiwan. J Formos Med Assoc. 2006;105(6):439-450.
7. Liu Z, Guo J. Dynamic changes of liver function and myocardial enzyme in 259 patients with severe acute respiratory syndrome. J Clin Hepatol. 2003;3:129-131.
8. Lu Y, Yin C, Tang X, et al. Clinical characteristics and mechanism of liver function injury in 250 patients with severe acute respiratory syndrome. Chin J Mod Med. 2004;23:121-123.
9. Tie Z, Zhang T, Zhang M, et al. Prevention and treatment of liver injury in SARS patients-222 cases analysis. Beijing Med J. 2004;5:318-320.
10. Zhao L, Xing H, Xu L. Effect of SARS associated coronavirus on peripheral blood picture and liver function. Chin Crit Care Med. 2004;11:660-663.
11. Yang Z, Xu M, Yi J. The clinic characteristics and mechanism of liver damage in patients with severe acute respiratory syndrome. Chin J Infect Dis. 2003;4:13-15.
12. Duan Z, Chen Y, Zhang J, et al. Clinical characteristics and mechanism of liver injury in patients with severe acute respiratory syndrome. Chin J Hepatol. 2003;11(8):493-496.
13. Huang Y, Gao Z. Study of the relationship SARS and hepatitis virus B. Chin J Clini Hepatol. 2003;6:342-343.
14. Wang J-T, Sheng W-H, Fang C-T, et al. Clinical manifestations, laboratory findings, and treatment outcomes of SARS patients. Emerg Infect Dis. 2004;10(5):818-824.
15. Jiang T, Zhao M, Zhou Z, et al. Clinical feature of liver injury in patients with severe acute respiratory syndrome. Chin J Mod Med. 2004;23:139-141.
16. Lu S-N, Lee C-M, Lin M-C, et al. Sequential changes of serum aminotransferase levels in patients with severe acute respiratory syndrome. Am J Trop Med Hyg. 2004;71(2):125-128.
17. Duan X, Liu Z, He R, et al. The dynamic change of liver injury in patients with severe acute respiratory syndrome. Chin J Hepatol. 2004;7:60.
18. Chau T-N, Lee K-C, Yao H, et al. SARS-associated viral hepatitis caused by a novel coronavirus: report of three cases. Hepatology. 2004;39(2):302-310.
19. Lu J, Zhao J, Li N, et al. Ultrastructure pathology of all organs in severe acute respiratory syndrome. Chin J Diag Pathol. 2003;4:72-77.
20. Ding Y, He LI, Zhang Q, et al. Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways. J Pathol. 2004;203(2):622-630.
21. Farcas G, Poutanen S, Mazzulli T, et al. Fatal severe acute respiratory syndrome is associated with multiorgan involvement by coronavirus. J Infect Dis. 2005;191(2):193-197.
22. Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426(6965):450-454.
23. Hamming I, Timens W, Bulthuis M, Lely AT, Navis GJ, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Patho. 2004;203(2):631-637.
24. Tan Y-J, Fielding BC, Goh P-Y, et al. Overexpression of 7a, a protein specifically encoded by the severe acute respiratory syndrome coronavirus, induces apoptosis via a caspase-dependent pathway. J Virol. 2004;78(24):14043-14047.
25. Yang Z, Xu M, Yi JQ, et al. Clinical characteristics and mechanism of liver damage in patients with severe acute respiratory syndrome. Hepatobiliary Pancreat Dis Int. 2005;4(1):60-63.
26. Zumla A, Hui DS, Perlman S. Middle East respiratory syndrome. Lancet. 2015;386(9997):995-1007.
27. Saad M, Omrani AS, Baig K, et al. Clinical aspects and outcomes of 70 patients with Middle East respiratory syndrome coronavirus infection: a single-center experience in Saudi Arabia. Int J Infect Dis. 2014;29:301-306.
28. Al-Hameed F, Wahla AS, Siddiqui S, et al. Characteristics and outcomes of Middle East respiratory syndrome coronavirus patients admitted to an intensive care unit in Jeddah, Saudi Arabia. J Intensive Care Med. 2015;31(5):344-348.
29. Hwang S-M, Na B-J, Jung Y, et al. Clinical and laboratory findings of Middle East respiratory syndrome coronavirus infection. Jap J Infect Dis. 2019;72(3):160-167.
30. Arabi YM, Al-Omari A, Mandourah Y, et al. Critically Ill patients with the Middle East respiratory syndrome. Crit Care Med. 2017;45(10):1683-1695.
31. Arabi YM, Arifi AA, Balkhy HH, et al. Clinical course and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus infection. Ann Intern Med. 2014;160(6):389-397.
32. Assiri A, Al-Tawfiq JA, Al-Rabeeah AA, et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis. 2013;13(9):752-761.
33. Ng DL, Al Hosani F, Keating MK, et al. Clinicopathologic, immunohistochemical, and ultrastructural findings of a fatal case of Middle East respiratory syndrome coronavirus infection in the United Arab Emirates, April 2014. Am J Patho. 2016;186(3):652-658.
34. Alsaad KO, Hajeer AH, Al Balwi M, et al. Histopathology of Middle East respiratory syndrome coronovirus (MERS-CoV) infection – clinicopathological and ultrastructural study. Histopathology. 2018;72(3):516-524.
35. Raj VS, Mou H, Smits SL, et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature. 2013;495(7440):251-254.
36. Boonacker E, Van Noorden CJF. The multifunctional or moonlighting protein CD26/DPPIV. Eur J Cell Biol. 2003;82(2):53-73.
37. Zhao G, Jiang Y, Qiu H, et al. Multi-organ damage in human dipeptidyl peptidase 4 transgenic mice infected with Middle East respiratory syndrome-coronavirus. PLoS ONE. 2015;10(12):e145561.
38. Mahallawi WH, Khabour OF, Zhang Q, Makhdoum HM, Suliman BA. MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile. Cytokine. 2018;104:8-13.
39. WHO. Coronavirus disease. 2019. http://www.who.int/emergencies/diseases/novel-coronavirus-2019. Accessed March 6, 2020.
40. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506.
41. Guan W, Ni Z, Hu Y, et al. Clinical characteristics of 2019 novel coronavirus infection in China. medRxiv. 2020; in press. https://doi.org/10.1101/2020.02.06.20020974
42. Cai Q, Huang D, Ou P, et al. COVID-19 in a Designated Infectious Diseases HospitalOutside Hubei Province, China. medRxiv. 2020; in press. https://doi.org/10.1101/2020.02.17.20024018
43. Fan Z, Chen L, Jun LI, et al. Clinical features of COVID-19-related liver damage. medRxiv. 2020; in press. https://doi.org/10.1101/2020.02.26.20026971
44. Wang D, Hu BO, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020.
45. Cao W. Clinical features and laboratory inspection of novel coronavirus pneumonia (COVID-19) in Xiangyang, Hubei. medRxiv. 2020; in press. https://doi.org/10.1101/2020.02.23.20026963
46. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507-513.
47. Shi H, Han X, Jiang N, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis, 2020. https://doi.org/10.1016/S1473-3099(20)30086-4
48. Xu X-W, Wu X-X, Jiang X-G, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ. 2020;m606.
49. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020. https://doi.org/10.1016/S2213-2600(20)30079-5
50. Zhang B, Zhou X, Qiu Y, et al. Clinical characteristics of 82 death cases with COVID-19. medRxiv. 2020; in press. https://doi.org/10.1101/2020.02.26.20028191
51. Huang Y, Zhou H, Yang R, et al. Clinical characteristics of 36 non-survivors with COVID-19 in Wuhan, China. medRxiv; 2020; in press. https://doi.org/10.1101/2020.02.27.20029009
52. Hoffmann M, Kleine-Weber H, Krüger N, et al. The novel coronavirus 2019 (2019-nCoV) uses the SARS-1 coronavirus receptor2 ACE2 and the cellular protease TMPRSS2 for entry into target cells. bioRxiv; 2020; in press. https://doi.org/10.1101/2020.01.31.929042
53. Chai X, Hu L, Zhang Y, et al. Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection. bioRxiv; 2020. https://doi.org/10.1101/2020.02.03.931766
54. Banales JM, Huebert RC, Karlsen T, Strazzabosco M, LaRusso NF, Gores GJ. Cholangiocyte pathobiology. Nat Rev Gastroenterol Hepatol. 2019;16(5):269-281.
55. Liu J, Li S, Liu J, et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. medRxiv, 2020, in press. https://doi.org/10.1101/2020.02.16.20023671
56. Xu Z, Shi L, Wang Y et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med, 2020. https://doi.org/10.1016/S2213-2600(20)30076-X
57. National Health Commission of the People's Republic of China. Diagnosis and Treatment of Coronavirus disease 2019 (Trial Version 7).http://www.nhc.gov.cn/yzygj/s7652m/202003/a31191442e29474b98bfed5579d5af95.shtml. Accessed March 6, 2020
58. Yu C, Mao Y. Guidelines for the management of drug-induced liver injury. J Prac Hepatol. 2017;20(02):257-274.
59. Guan Y, Zheng BJ, He YQ, et al. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science. 2003;302(5643):276-278.
60. WHO. Severe Acute Respiratory Syndrome (SARS). 2020. http://www.who.int/csr/sars/en/. Accessed Feburary 24, 2020
61. WHO.Middle East respiratory syndrome coronavirus (MERS-CoV).https://www.who.int/emergencies/mers-cov/en/. Accessed Feburary 24, 2020
62. Xiao K, Zhai J, Feng Y, et al. Isolation and characterization of 2019-nCoV-like coronavirus from Malayan pangolins. bioRxiv. 2020. https://doi.org/10.1101/2020.02.17.951335